The trial attained the two its primary endpoints, with semaglutide 2.four mg demonstrating statistically substantial and exceptional improvements in liver fibrosis without worsening of steatohepatitis, together with resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH in comparison to placebo.onePancreatiti